Therapeutic agents with novel mechanisms of action are urgently needed to counter the emergence of drug-resistant infections. Several decades of research into proteases of disease agents have revealed enzymes well suited for target-based drug development. Among them are the three recently validated proteolytic targets: proteasomes of the malarial parasite Plasmodium falciparum, aspartyl proteases of P. falciparum (plasmepsins) and the Sars-CoV-2 viral proteases. Despite some unfulfilled expectations over previous decades, the three reviewed targets clearly demonstrate that selective protease inhibitors provide effective therapeutic solutions for the two most impacting infectious diseases nowadays—malaria and COVID-19.
All Keywords
【저자키워드】 therapy, Infectious diseases, protease, parasites, inhibition, 【초록키워드】 COVID-19, Infectious diseases, Infectious disease, malaria, Protease inhibitor, infections, Viral, therapeutic, Research, target, therapeutic agent, therapeutic agents, Proteases, Enzymes, disease, mechanism, Plasmodium falciparum, malarial parasite, enzyme, P. falciparum, selective, effective, drug-resistant, proteolytic, 【제목키워드】 Strategy, Infectious disease, combat,
【저자키워드】 therapy, Infectious diseases, protease, parasites, inhibition, 【초록키워드】 COVID-19, Infectious diseases, Infectious disease, malaria, Protease inhibitor, infections, Viral, therapeutic, Research, target, therapeutic agent, therapeutic agents, Proteases, Enzymes, disease, mechanism, Plasmodium falciparum, malarial parasite, enzyme, P. falciparum, selective, effective, drug-resistant, proteolytic, 【제목키워드】 Strategy, Infectious disease, combat,
약물 내성 감염의 출현에 대응하기 위해 새로운 작용 기전을 가진 치료제가 시급히 필요합니다. 질병 인자의 프로테아제에 대한 수십 년간의 연구는 표적 기반 약물 개발에 매우 적합한 효소를 밝혀냈습니다. 그 중에는 최근에 검증된 세 가지 단백질 분해 표적이 있습니다. 말라리아 기생충 Plasmodium falciparum의 프로테아좀, P. falciparum(플라스메신)의 아스파르틸 프로테아제 및 Sars-CoV-2 바이러스 프로테아제입니다. 지난 수십 년 동안 충족되지 않은 기대에도 불구하고, 검토된 세 가지 목표는 선택적 프로테아제 억제제가 오늘날 가장 영향을 미치는 두 가지 전염병인 말라리아와 COVID-19에 대한 효과적인 치료 솔루션을 제공한다는 것을 분명히 보여줍니다.